Measure biomarkers at lower levels than ever before
Quanterix’ digital biomarker detection technology, Simoa®, is changing the way in which the biology of health and disease is studied by giving researchers the ability to examine critical proteins and nucleic acids, at ultra low – even baseline – levels, in most common sample types.
Simoa® Technology
Simoa® Planar Array Technology
An incredibly simple, flexible, robust, and ultra-sensitive immunoassay platform for measuring up to 10-plex biomarkers. Its unique capabilities are designed specifically to address many of today’s unmet needs in immuno-oncology and other research areas.
- Proprietary, high-precision, digital nanofluidic antibody deposition
- Reaction kinetics optimized by fluid dynamics
- Optimized image quality and dynamic range
How Simoa Planar Technology Works
A high level look at a Simoa Planar Array assay, from initiation to imaging.
96-well plates are spotted at the factory with the target analyte(s) of interest
Diluted samples and standards added to each well and the plates are to create a unique surface chemistry and “vortex” effect
Biotinylated detection antibodies are added to form the other half of the immunocomplex “sandwich”
High sensitivity HRP enzyme-conjugated streptavidin is added in between additional shake cycles.
Finally, a chemiluminescent substrate is added just prior to ultra-sensitive CCD camera imaging, in order to measure the signal intensity produced by each spot.
Simoa® Bead Technology
Quanterix’ digital biomarker detection technology, Simoa®, is changing the way in which the biology of health and disease is studied by giving researchers the ability to examine critical proteins and nucleic acids, at ultra low – even baseline – levels, in most common sample types.
- First of its kind detection capabilities
- Detect biomarkers at femtogram levels
- See results in record time
How Simoa Bead Technology Works
A high-level look at a Simoa Bead-based assay, from development to data analysis.
Paramagnetic particles coupled with antibodies designed to bind to specific targets are added to the sample
Detection antibodies – capable of generating fluorescent product – are added.
The objective is to form an immunocomplex consisting of the bead, bound protein, and detection antibody.
At low concentrations, each bead will contain one bound protein, or none.
The sample is loaded into arrays, in the Simoa disc, consisting of more than 200,000 microwells – each large enough to hold one bead.
Enzymatic signal amplification with fluorescent substrate, fluorescence imaging and data reduction.
Data analysis – results can be viewed and analyzed on the board or exported to commonly used software packages or LIMS systems.
Instruments
Offers researchers access to ultra-sensitive biomarker detection capabilities in a compact and affordable system.
Up to 1000x greater sensitivity
Up to 4 biomarkers in a single assay
Compatible with 30+ assays
Introducing the world’s most sensitive, fully automated immunoassay platform with multiplexing and custom assay capability.
Up to 1000x greater sensitivity
Up to 4 biomarkers in a single assay
Compatible with 80+ assays
Unleashing the power of next-generation Simoa® Planar Array technology for robust multiplex biomarker detection – even at healthy baseline levels.
Up to 1000x greater sensitivity
Up to 10 biomarkers in a single assay
Compatible with 100+ assays
Cancer
Mapping the Tumor Immune Microenvironment: Spatial Biology Insights into Immunotherapy Response in NSCLC
Lung cancer is a formidable foe. Globally, it is the leading cause of cancer-related deaths in men and women, with non-small lung cancer (NSCLC) representing more than 80% of all…
Synaptic Dysfunction and Neuroinflammation: Complementary Pathways Driving Cognitive Decline
Accelerator Laboratory Services: The Biomarker Powerhouse
Proteomics in Transition: From Discovery to Diagnostic Utility
The promise of proteomics lies in its ability to illuminate disease biology at scale, transform translational research, and guide the development of precision diagnostics and targeted therapies. While genomic technologies…
Built for Translation: Why Simoa Stands Alone in Clinical-Grade Biomarker Measurement
Translating proteomic discovery into clinical action requires more than scale, it demands precision, reproducibility, and quantitative clarity. The Quanterix Simoa® digital immunoassay technology was purpose-built to meet the demands of…
YKL-40 Emerges as a Key Indicator of Neuroinflammatory-Driven Tau Pathology and Brain Atrophy in Alzheimer’s Disease
Alzheimer’s disease (AD) is increasingly understood as a multifaceted disorder involving not only amyloid and tau pathology, but also significant contributions from neuroinflammation and vascular dysfunction. In particular, astrocyte reactivity…
Looking Ahead: Key Takeaways from AAIC 2025
The 2025 Alzheimer’s Association International Conference (AAIC) brought the global neuroscience community to share breakthrough science, policy priorities, and tools like never before. It was an incredible week of conversation, innovation and…
Neurology
AAIC 2025: A Showcase of Simoa-Powered Innovation and Integration in Alzheimer’s Research
Next week, researchers from around the globe will gather in Toronto for the Alzheimer’s Association International Conference (AAIC) 2025, and Quanterix is proud to be at the center of the…
Quanterix Releases Financial Results for the Second Quarter of 2026
Reports $32.9 million in revenue and $96.9 million of cash and marketable securities Company accelerating initiatives to drive commercial effectiveness Revises financial outlook for 2026 and extends date for attaining…
Quanterix Names Jim Gute Chief Commercial Officer
Brings 20 years of senior commercial leadership in healthcare and IT, including GE Healthcare and Exact Sciences BILLERICA, Mass.–August 10, 2026–Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker…
Quanterix To Participate in Canaccord Genuity Capital Markets 46th Annual Growth Conference on August 11-12
BILLERICA, Mass. – August 6, 2026 – Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that senior management will participate in the Canaccord Genuity Capital…
Quanterix To Report Second Quarter 2026 Financial Results on August 10, 2026
BILLERICA, Mass. – August 4 2026 – Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that it will host a conference call on Monday, August…
Anthem Blue Cross and Blue Shield Establishes Commercial Coverage for LucentAD® Complete; Quanterix to Present New Data Highlighting Multi-Analyte Advantages
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BILLERICA, Mass. – June 16, 2026 – Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that on June 15,…
Quanterix Announces Appointment of Jason Faessler as Chief Financial Officer
BILLERICA, Mass.—June 9, 2026– Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the appointment of Jason Faessler as the Company’s new Chief…
Quanterix Appoints Industry Veteran Geoff Albrecht as Senior Vice President and General Manager of Diagnostics
Strategic Leadership Addition Signals Drive to Expand Diagnostics Business BILLERICA, Mass.–June 4, 2026– Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the…
Accelerate Building Custom Spatial Proteomic Panels for New Biological Insights
Ultrasensitive Neuroimmune Biomarker Measurement for Translational Research and Therapeutic Development
Underdiagnosis of Alzheimer’s disease pathology in patients with cardiovascular disease
Decoding Neurodegeneration: High-plex Spatial Proteomics Reveal Distinct Cell Phenotypes and Pathological Signatures in Parkinson’s and Alzheimer’s Disease
In this webinar, Dr. Birgitt Schuele, Associate Professor (Research) of Pathology at Stanford University, showcases how ultrahigh-plex spatial proteomics is being used to uncover distinct cell phenotypes and pathological signatures…
Understanding the Brain: Advancing Neurodegeneration Research with Ultrahigh-Plex Spatial Proteomics
In this webinar, learn how ultrahigh-plex spatial phenotyping has been applied to neurodegenerative disease research.
p-Tau 205 and p-Tau 212: Emerging Biomarkers for Alzheimer’s Disease Research
Spatial Awareness: AI-powered Profiling of Trillions of Immune Cell Distribution Data Points Reveals Key Predictors of Cancer Recurrence Risk
This webinar highlights a groundbreaking study recently published as a Nature cover story (April 2025). Dr. Joe Yeong will describe how a pre-designed analytical framework—driven by well-defined clinical and scientific…
Multimodal Single-Cell Spatial Transcriptomics and Proteomics to Uncover the Biological Processes Driving Immunotherapy Response and Resistance in Renal Cancer
In this webinar, Dr. Anne-Laure Cattin from the Cancer Dynamics Laboratory at The Francis Crick Institute in London, will share her research on kidney cancer, focusing on the integration of…